Predictive Oncology agrees to be acquired by Renovaro for $3.00/share in preferred stock

Axe Compute Inc.

POAI shareholders to receive 1 share of Renovaro preferred stock per POAI share, redeemable for $3.00 after 18 months.
Preferred stock convertible to Renovaro common at 1:1 after RENB trades at $4.50+ for 30 consecutive days.
Renovaro to purchase up to 2.33M POAI shares at $1.07 if warrants unexercised by Jan 15, 2025.
Merger conditioned on Renovaro raising $15M and POAI shareholder approval; definitive docs by Feb 28, 2025.
Combined company expects >30% near-term operating expense reduction via AI/ML platform synergies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.